Frontlight ResearchEarly access
CompletedPhase 1
An open-label, randomised, single-dose, three-way cross-over trial to assess the pharmacokinetics of NIC24-01 and NIC24-02 oromucosal pouches (a nicotine replacement therapy) in comparison to Nicorette® 4 mg gum in healthy adult smokers under fasted conditions.
Key facts
- Who runs it
- Niconovum AB
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 15 people enrolled
- Started
- 12 Dec 2024
- Ended
- 30 Jan 2025
- Type of study
- Interventional
- Record updated
- 21 November 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 21 November 2024